|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Ingrezza
Dopamine Therapeutics
|
|
gptkbp:ceo
|
Kevin Gorman
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
NBI-74788
NBI-921352
NBI-98854
|
|
gptkbp:collaboration
|
gptkb:Pfizer
gptkb:Lundbeck
gptkb:Takeda
|
|
gptkbp:employees
|
over 500
|
|
gptkbp:focus
|
neurological diseases
|
|
gptkbp:focus_area
|
neurological diseases
endocrine diseases
|
|
gptkbp:founded
|
gptkb:1992
|
|
gptkbp:founder
|
Kevin Gorman
|
|
gptkbp:headcount
|
over 500
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
gptkbp:healthcare
|
gptkb:Ingrezza
gptkb:Vraylar
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Neurocrine Biosciences
|
|
gptkbp:investment
|
Venture capital
$100 million (2021)
|
|
gptkbp:market_cap
|
$5 billion (2023)
|
|
gptkbp:partnership
|
gptkb:Acorda_Therapeutics
gptkb:Abb_Vie
gptkb:Sage_Therapeutics
Neurocrine Biosciences and Abb Vie
|
|
gptkbp:product
|
gptkb:Ingrezza
gptkb:Vraylar
|
|
gptkbp:research_areas
|
movement disorders
psychiatric disorders
endocrine disorders
hormonal disorders
CNS disorders
|
|
gptkbp:revenue
|
$300 million (2022)
|
|
gptkbp:stock_symbol
|
gptkb:NBIX
|
|
gptkbp:subsidiary
|
gptkb:Neurocrine_Biosciences_International
Neurocrine Biosciences Asia
Neurocrine Biosciences Europe
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.neurocrine.com
|
|
gptkbp:bfsParent
|
gptkb:Abb_Vie
|
|
gptkbp:bfsLayer
|
4
|